. Regeneration of rhodopsin pigment in the presence of RS1-4. Absorbance changes measured at by UV/VIS at 498 nm indicate the formation of a stable 11-cis retinalopsin complex (rhodopsin) after mixing 20 µM 11-cis retinal and bovine rod outer segment disc membranes containing 3 µM opsin.. Membranes were premixed with no or 120 µM compound S-RS1 or RS2-4 and incubated for 30 minutes at 20 °C in a buffer containing 60 mM phosphate buffer pH 6.5 with 0.01 % (w/v) n-decyl-β-D-maltopyranoside. Half-time values for pigment formation were determined by background subtraction and one-phase association fit in Graph Pad Prism (not shown) yielding 3 min for 11-cis retinal, 6.2 min for RS1, 7.6 min for RS2, 3.8 min for RS3 and 4 min for RS4, respectively. The presence of S-RS1 and RS2 thus resulted in significantly reduced rates of pigment formation indicative for binding in the orthosteric binding pocket. Notably, none of the compounds prevented formation of stable rhodopsin pigment. Key interactions between S-RS1 derivatives and opsin detailing hydrophilic residues (purple), basic groups (blue rings), acidic groups (red rings), hydrophobic residues (green), hydrogen bonds (arrows) and blue discs on ligand atoms indicate solvent exposure when bound, light blue shadows indicate contact surface area. .524 μM and 119.048 μM using 1.3 μM human opsin N2C N282C. An EC 50 value of 0.8 μM is determined for the S enatiomer. Rather than binding, we observe a destabilizing effect for human opsin for the R-RS1 at concentrations above 15 μM. All data points were measured in triplicates and the data is shown as mean ± S.D.. Side view of superimposed dark state (blue; PDB ID: 1GZM), meta-II active state rhodopsin (bluewhite; PDB ID: 3PQR) and S-RS1-bound opsin (red, opsin structure omitted, only S-RS1 shown). The β-ionone ring of the agonist all-trans retinal (dark state conformation, bluewhite) overlaps with the chlorinated phenyl ring of S-RS1 (red), whereas the β-ionone ring of the inverse agonist 11-cis retinal (metaII active conformation, blue) overlaps with the location of the spiro group of S-RS1. S-RS1 stabilizes the novel conformation by addressing locations known to be critical to generate retinal-bound dark state or metaII active conformations.
Key interactions between S-RS1 derivatives and opsin detailing hydrophilic residues (purple), basic groups (blue rings), acidic groups (red rings), hydrophobic residues (green), hydrogen bonds (arrows) and blue discs on ligand atoms indicate solvent exposure when bound, light blue shadows indicate contact surface area.
Fig. S8: Side view of a ligand channel in S-RS1
-stabilized opsin. a, Combined surface and cartoon representation of the S-RS1-octylglucoside-opsin complex sliced perpendicular to the membrane. The view highlights an intradiscal opening formed between L2 ("ECL2"), TM5 and TM6a as well as an opening towards the membrane providing enough space for the exchange of hydrophobic molecules. Overlayed S-RS1 and octylglucoside molecules indicate locations rather than exact positions or slice. b, S-RS1-octylglucoside-opsin complex in cartoon representation in the non-sliced, analogous view of a to visualize exact S-RS1 and octylglucoside positions and clearly assignable transmembrane helices. Cartoon representation of the S-RS1-opsin complex showing residues of low conservation using thin green, and a high conservation in thick red lines. Sequences exhibit a very high sequence similarity as shown by color intensity (color intensity panel). Residues along the intradiscal opening shaped by L2 ("ECL2"), TM5 and TM6a are highly conserved (left panel close-up), whereas the level of conservation appears to be lower for the membrane opening between TM7/TM1 suggesting kinetic influences for ligand entry or exit (right panel close-up). Residues important for the retinal uptake and release are highlighted in stick. 
SI Experimental Procedures
Selection of focused library Five complementary in silico methods were used to compile the focused library screened in this study. All-trans retinal served as the reference molecule for a 2D ligand similarity search in the Roche compound library using Pipeline Pilot ECFP6 fingerprints (1) . In addition, three published non-covalent opsin binders (2, 3) were used as templates for similarity searches using the graph-based Maximum Overlapping Set (MOS) approach available in Spinifex and 3D shape matching as implemented in ROCS (4, 5) . The 3D coordinates for reference molecules were generated with the Moloc companion program Mol3d using default parameters (6) . The crystal structure of rhodopsin with bound all-trans retinal (PDB ID: 4A4M) was used as template for a MOE pharmacophore model including five hydrophobic features covering the β-ionone ring and the region close to the ligand head group, as well as excluded volume features for the surrounding protein except for the flexible, retinal-binding Lys296 7.43 (7) . Additional pharmacophore searches were performed with models mimicking a potential covalent interaction with Lys296 7.43 . These were constructed again from the crystal structure of rhodopsin with bound all-trans retinal using the same protein excluded volume features as before but combined with pharmacophore features for potential ligand reactive groups. The ligand sub-structures included activated double bonds, activated ketones, aldehydes, nitriles, and sulfonylhalides, which were defined using SMARTS patterns. As a fifth approach, we used GOLD docking (8, 9) with the ChemScore scoring function to both an active (PDB ID: 4A4M) and inactive (PDB ID: 1GZM) conformation of rhodopsin (7, 10) . The docking was performed in GOLD library screening mode with an additional hydrogen bonding constraint between any ligand atom and NZ of Lys296 7.43 . The residue was allowed to relax during docking. Top-ranked compounds from each in silico approach were retrieved based on method-specific score thresholds and further pruned in MOE by removing undesired substructures and filtering by the following molecular properties: a) number of heavy atoms: 10-32, b) calculated lipophilicity SlogP >2, c) number of hydrogen bond donors: 0-5. Finally, a chemically diverse subset of the remaining compounds was selected yielding a focused library of 4617 molecules. Whereas the majority of the selections were non-covalent binders, a smaller subset contained compounds with functional groups and the potential to form a covalent interaction with Lys296 7.43 . After screening of this library one round of hit expansion was performed resulting in 5186 molecules tested in total.
Constructs, expression and purification
A detailed description of the cloning, expression, purification and crystallization process can be found here (11) . Briefly, full length native human opsin (P08100) stabilized by the functionally neutral disulfide bridge between mutations N2C and N282C (corresponding to N2C/D282C in bovine rhodopsin (12, 13) was subcloned into a tetracycline-inducable pCMV vector for expression in HEK293S GnTI-stable cell lines (14) (15) (16) . Large scale expression of human opsin was performed in 100 l bioreactors and purified using 1D4 antibody affinity resin (Cubebiotech) by gravity flow. Eluted protein was flash frozen in liquid nitrogen and elution buffer containing 10 mM Hepes-NaOH pH 7.0, 0.125 % (w/v) DM, 80 µM elution peptide (TETSQVAPA) at 5 mg/ml until further use in thermofluor differential scanning fluorimetry (DSF) or fluorescence-detection size-exclusion chromatography thermal shift (FSEC-TS) assays. For crystallization, stabilized bovine opsin N2C/D282C (P02699) was expressed in HEK293S GnTI-stable cell lines and purified. To equilibrate the protein in crystallization buffer containing 10 mM NaOAc-HCl pH 5.0, 100 mM NaCl, 1 % (w/v) b-OG an additional size-exclusion chromatography step was added using a superdex 200 10/300 GL (GE Helthcare).
Crystal soaking, data collection and structure determination of opsin complexes. Crystals were readily obtained using purified bovine opsin N2C/D282C incubated with 0.5-1 times w/w porcine brain polar lipid prior to vapor diffusion sitting or hanging drop crystallization (11). Crystals were grown over a reservoir solution containing 3.0 to 3.5 M ammonium sulfate, 0.1 M sodium acetate pH 5.75 -6.0 and 10 % (w/v) trehalose as cryoprotectant. Soaks with 3.75 to 5 mM of compounds were incubated for 24 h prior to flash cooling of crystals with liquid nitrogen. Diffraction data were collected at 100 K on beamline X10SA at the Swiss Light Source. Data sets were integrated using XDS and scaled using SADABS (17) . All structures were solved by molecular replacement in Phaser with a rhodopsin search model (PDB ID 4J4Q) (18, 19) . Iterative model building was done with Coot followed by refinement in Phenix (20, 21) . Caver was used to analyze cavities in the dark state (PDB ID: 1GZM), the meta-II state (PDB ID: 3PQR) and the S-RS1-opsin complex (22) (23) (24) (25) . Statistics of structure determination are listed in Supplementary Table 1 .
Focused screening
A thermofluor assay was adapted and automated to screen the focused library and compounds from hit expansion (26) . Briefly, purified human opsin N2C/N282C was diluted to 1.4 µM with assay buffer containing 10 mM HEPES-NaOH pH 7.4, 200 mM NaCl, 0.125 % (w/v) DM, distributed to 72 positions in a 96 well plate and incubated either with 47.6 µM compound or 1.2 % (v/v) DMSO in the first and last position for 30 minutes at room temperature. The total reaction volume was 42 µl. Next, 3 mg/ml N-4-(7-diethylamino-4-metyl-3-coumarinyl)phenyl]malemeide (CPM; Molecular Probes, REFD346) in DMSO (Molecular Probes, REF D12345) was diluted to 0.03 mg/ml in assay buffer. Finally, a concentration of 0.006 mg/ml CPM dye was used to investigate the thermal denaturation of the compound-bound ospin in a total reaction volume of 52 µl 28, 29 . Melting curves were obtained applying a temperature gradientfrom 25 to 95 °C and a heating rate of 0.25 °C/s in a Rotor Gene Q (Qiagen). All liquid handling steps were performed using a Bravo Automated Liquid handling platform and a 96LT head (Agilent). Melting temperatures (T M ) were calculated and analyzed by automated scripts using Spotfire (Tibco) and the Boltzmann equation ( = + − 1+ − ) the minimal and maximal temperatures T min and T max , respectively. Compounds were selected for further characterization based on a stabilizing effect exceeding the threshold of two standard deviations (±2.6 °C) of human opsin N2C/N282C containing DMSO (27) . Hits served as reference molecules for a 2D ligand similarity search performed with ECFP6 (1). The hit expansion identified another 569 compounds for screening and characterization.
Hit validation using a fluorescence-detection size-exclusion chromatography thermal shift assay (FSEC-TS) FSEC-TS served as an orthogonal thermal shift assay to validate the compound-induzed stabilization of human opsin N2C/N282C (28) . Each measurement consumed 0.26 µM protein mixed with 10 µM of compound in a final buffer containing 10 mM HEPES-NaOH pH 7.4, 200 mM NaCl, 0.125 % (w/v) DM and 0.1 % (v/v) DMSO and incubated for 30 minutes at 4 °C. Melting temperatureswere determined in duplicate by incubation for 10 minutes in a Prime Thermal cycler (Techne) at 12 different temperaturesbetween 35 °C and 60 °C.Non-aggregated protein was quantified using tryptophan fluorescence after separation on a high-performance liquid chromatography system (Agilent 1200). Melting temperatures (T m ) were determined using the Boltzmann equation fit ( = + − 1+ − ) with the minimal and maximal temperature T min and T max , respectively. All analysis were performed in GraphPad Prism (GraphPad Software, Inc.).
Mouse P23H opsin pharmacotrafficking β-galactosidase complementation assay U2OS mouse rhodopsin P23H stable cell lines (DiscoverRx ID 93-1077C3) were used to express a C-terminal fusion of mouse opsin P23H with the small β-galactosidase subunit. The large subunit of β-galactosidase was fused to the plasma membrane-expressed pleckstrin homology domain of phospholipase C-δ (29) . Cells were cultured in AssayComplete Cell Culture Media (Cat. No. 92-0018GK3, DiscoverX), grown to approximately 80 % confluency and routinely passages were produced every 2-3 days. A Countess™ automated cell counter (ThermoFisher Scientific) was used to determine the cell density measurements. For final measurements, the cell medium was exchanged to AssayComplete™ CP reagent (Cat. No. 93-0563R5A; DiscoverX). Approximately 5000 cells in a total volume of 40 μl were transferred to each of a well of a 384-well plate and incubated for 4 h at 37 °C in 5 % CO 2 . Compounds including the positive control 9-cis retinal were added at a final concentration of 5 µM. 4 % (v/v) DMSO served as negative control. Cells were incubated for 20 h at 37 °C in 5 % CO 2 followed by an additional incubation step at room temperature for 3 h before chemiluminescence measurement. Detection was performed with PathHunter Detection Kit reagent (Cat No. 93-0001S, DiscoverX) following the protocol provided by DiscoverX. Chemiluminescence measurements were performed after 1 h of incubation on a BioTek Cytation3 luminescence plate reader. Measurements were evaluated and compared to 9-cis retinal with GraphPad Prism using the normalised dose-response curve, while the lowest value was defined as 0 % and the highest value as 100 % in a compound dataset. All experiments were done under red-light due to the instability of 9-cis retinal under normal light conditions.
Compound synthesis and characterization
To perform the macromolecular crystallographic analysis and biophysical characterization of RS1, the racemate was synthesized (Chembiotek, India) and purified to yield the R-and Senantiomer. Reactions were performed under an atmosphere of argon. Solvents and reagents were obtained from commercial sources and used without further purification. All reactions were monitored by thin-layer chromatography (TLC) on Merck silica gel 60 F254 TLC glass plates (visualized by UV fluorescence at λ = 254 nm). Chlorophenyl)-3-methyl-1-{spiro[1,3-benzodioxole-2,4'-piperidine]-1'-yl}butan-1-one (2a; RS1) : To a solution of 2-(4-chloro-phenyl)-3-methyl-butyric acid (1a, 0.5 g, 2.61 mmol) in THF (4 mL) was added spiro[1,3-benzodioxole-2,4'-piperidine] (0.66 g, 3.13 mmol), T3P (1.0 mL, 3.92 mmol) and Et3N (0.7 mL, 5.23 mmol) at rt. The reaction was stirred at rt for 16 h and then diluted with water (30 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layer was washed with brine, dried over anhydrous Na2SO4 and evaporated under reduced pressure. Purification by column chromatography using silica gel (100-200 mesh) (20 % EtOAc in n-hexane) afforded 2a (0.4 g, 40 %) as a white solid. LC-MS: t R 3.71 min, 100 % (265 nm); t R 3.71 min, 100 % (220 nm). HT Instrument using a YMC C18 5u (250*4.6 mm) column operated at ambient temperature and a flow rate of 1.0ml/min. The following scheme was applied: mobile phase from 90 % (10 mM NH 4 OAc in water) and 10 % acetonitrile for 0.01min, mobile phase from 10 % (10 mM NH 4 OAc in water) and 90 % acetonitrile for 7 min, held in this composition up to 20 min, then returned to initial composition in 21 min. The two enantiomers of 2a (100 mg) were separated on a Reprosil Chiral NR column (20 % EtOH in n-heptane) to give after precipitation from CH2Cl2 with n-pentane (-) 1446 . Single crystals were formed at RT over time, suitable for X-ray crystallographic analysis. A single crystal was mounted in a loop and cooled to 130 K in a nitrogen stream. Data were collected on a Gemini R Ultra diffractometer (Rigaku) with Cu-Kalpha-radiation (1.54184 Å) and processed with the Crysalis-package. Structure solution and refinement was performed using the ShelXTL software (Bruker AXS, Karlsruhe) (SI Appendix, Table S4 Data were collected on a Gemini R Ultra diffractometer (Rigaku) with Cu-K-alpha-radiation (1.54184 Å) and processed with the Crysalis-package. Structure solution and refinement was performed using the ShelXTL software (Bruker AXS, Karlsruhe) (SI Appendix Table S4 ). 97 mmol). The reaction was stirred at room temperature for 8h and was then diluted with water (20 mL) and extracted with EtOAc (2 X 20 mL). The combined organic layer was washed with brine, dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure to afford 0.28 g crude compound which was purified by prep HPLC to afford 2c (0.05 g, 15 %) as an off white solid. LC-MS: t R 3.88 min, 100 % (265 nm); t R 3.88 min, 100 % (220 nm). 56 mmol) at rt. The resulting mixture was stirred at room temperature for 16h and was then diluted with water (10 mL) and extracted with EtOAc (3 X 10 mL). The combined organic layer was washed with brine, dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. Purification by column chromatography (100-200 mesh silicagel; 20 % EtOAc in n-hexane) afforded 2d (0.045 g, 46 %) as an white solid. LC-MS: t R 3.52 min, 100 % (265 nm); t R 3.52 min, 100 % (220 nm). 24 mmol) at 0 °C. The resulting mixture was stirred at room temperature for 16h. After completion, monitored by TLC, conc. aq. HCl was added dropwise to the solution until the pH of the mixture dropped below 4 and a white solid precipitated. Methanol was removed by vacuum, water was added to the residue and washed with DCM (25 mL). Then 6M aq NaOH was added to the aqueous layer to raise the pH to >12 and extracted with DCM (3 x 20 mL). 
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